We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The test can be used for initial diagnosis or for confirming the results of rapid tests with lower performance, such as antigenic tests, the company said. Read More
The head biosafety expert for China’s Center for Disease Control and Prevention has claimed that the country could have a vaccine ready for general population use as soon as November, touting the country’s rapid progress on COVID-19 vaccine development. Read More
Novavax has expanded its COVID-19 vaccine manufacturing agreement with the Serum Institute of India to produce more than 2 billion doses of the vaccine annually. Read More
In letters sent yesterday, leaders of the House Energy and Commerce committee urged nine companies developing COVID-19 vaccines to uphold their pledge to maintain high ethical standards and to commit to transparency in making all clinical trial data on their vaccines publicly available. Read More
The National Institutes of Health (NIH) is deeply concerned that an unexplained patient illness under review in AstraZeneca (AZ)’s phase 3 COVID-19 vaccine trial could throw the promising candidate off course, and the NIH has opened its own investigation into the issue, an NIH clinical director has disclosed. Read More
China’s state-owned pharmaceutical company, Sinopharm, said that it has already vaccinated hundreds of thousands in the country with its COVID-19 vaccine candidates, even though its phase 3 trials have not yet wrapped up. Read More
A late-stage trial of Eli Lilly’s rheumatoid arthritis (RA) treatment Olumiant (baricitinib) and Gilead Sciences’ remdesivir found that the combination reduced recovery time in hospitalized COVID-19 patients compared to remdesivir alone. Read More
The UK government has signed a $1.5 billion agreement with Valneva to supply up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million. Read More
Regeneron Pharmaceuticals’ investigational COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial aimed at finding effective treatments. Read More